Comparing the medication costs of treating patients with schizophrenia who use cannabis with those who do not.
Nikhil NowbathNada AbdelatifGian LippiPublished in: The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa (2024)
This study contributes to findings that it is more expensive to treat patients with schizophrenia who have relapsed, if they are using cannabis. This finding has future cost implications when budgeting for pharmacotherapeutic treatment.